Skip to main content
Equibles
BFRI logo

BFRI · Biofrontera Inc. · Metrics

Track BFRI — free

Use BFRI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BFRI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.83 +0.02 (+2.50%) At close · Nov 6 Play latest call Q1 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Aug 13, 2026
Market Cap
$12.30M
Shares
14.85M
Volume · Nov 6 209.3K Avg daily vol (3M) 490.11K

BFRI metrics

73 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.83
Market cap
$12.30M

Price action

23 metrics
Price change (1W)
-13.3%
Price change (30D)
-13.6%
Price change (3M)
-35.4%
Price change (6M)
-29.1%
Price change (YTD)
+41.7%
Price change (1Y)
-25.9%
Trailing year
Price change (5Y)
—
52-week high
$1.61
52-week low
$0.57
Change from 52-week high
-49.8%
Change from 52-week low
+41.7%
Annualized volatility
81.5%
Annualized volatility (3M)
75.2%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.7
RSI (14D)
37.6
Price vs SMA 50
-26.8%
Price vs SMA 200
-21.9%
Avg volume (3M)
491,182
Relative volume
0.3
Average dollar volume
$635,173

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
14.85M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 384.9%
P / book
2.0
reciprocal yield 49.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-53.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
—
Operating margin
-14.2%
Trailing 12 months
Net margin
-13.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$6.57M
Net income (TTM)
−$6.37M
Trailing 12 months
Diluted EPS (TTM)
$-0.46
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$3.91
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.60
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.59
Operating cash flow per diluted share (TTM)
$-0.69
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.26
Stock compensation per diluted share (TTM)
$0.10
Book value per share
$0.90

Growth

11 metrics
Revenue growth YoY
+32.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$46.17M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+38.2%
Year over year · more shares
Revenue CAGR (3Y)
+13.3%
Revenue CAGR (5Y)
+17.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-106.9%
Return on assets
-26.5%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
−$6.36M
Free cash flow (TTM)
—
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$4.66M
Total assets
$24.06M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.93M
Capital expenditures (TTM)
$3,000
R&D (TTM)
$2.99M
SG&A (TTM)
$39.19M
Stock compensation (TTM)
$1.13M
R&D / revenue
6.5%
Stock compensation / revenue
2.4%

Ownership (13F)

9 metrics
13F filers
23
13F filer change QoQ
+7
Institutional ownership
19.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
9.4%
Private-fund adviser ownership
2.1%
Active holders' share change QoQ
+16.2%
Holder tenure
8.0
Price vs estimated holder cost
-7.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.1%

Short interest

3 metrics
Short interest
0.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1858685 CUSIP 09077D209 13F (30d) 5 filings 5 filers Visit website Investor relations